Evercore ISI reiterated their buy rating on shares of electroCore (NASDAQ:ECOR) in a report issued on Tuesday, AnalystRatings.com reports.

“We think the TETRAS-ADL endpoint was most interesting (see image at bottom) … and this will be the primary endpoint in future clinical trials.”,” Evercore ISI’s analyst wrote.

Several other research analysts have also weighed in on the stock. Noble Financial set a $19.00 price objective on shares of electroCore and gave the company a buy rating in a research note on Friday, May 31st. Zacks Investment Research upgraded shares of electroCore from a sell rating to a hold rating in a research note on Monday, May 27th. ValuEngine upgraded shares of electroCore from a hold rating to a buy rating in a research note on Thursday, August 1st. Cantor Fitzgerald lowered shares of electroCore from an overweight rating to a neutral rating and dropped their price objective for the company from $19.00 to $9.00 in a research note on Thursday, May 30th. Finally, BTIG Research lowered shares of electroCore from a buy rating to a neutral rating in a research note on Wednesday, May 15th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. electroCore has an average rating of Buy and a consensus price target of $14.00.

electroCore stock opened at $1.56 on Tuesday. The firm has a market cap of $44.44 million, a price-to-earnings ratio of -1.31 and a beta of 2.84. The company has a current ratio of 10.74, a quick ratio of 10.07 and a debt-to-equity ratio of 0.08. The company has a 50 day moving average of $1.56. electroCore has a twelve month low of $1.23 and a twelve month high of $17.99.

electroCore (NASDAQ:ECOR) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.04. electroCore had a negative net margin of 4,450.22% and a negative return on equity of 66.37%. Research analysts expect that electroCore will post -1.57 EPS for the current fiscal year.

In other electroCore news, Director Thomas J. Errico purchased 21,000 shares of the company’s stock in a transaction dated Thursday, June 6th. The shares were bought at an average price of $1.77 per share, for a total transaction of $37,170.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 43.78% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. raised its position in shares of electroCore by 1.8% during the 4th quarter. BlackRock Inc. now owns 280,813 shares of the company’s stock worth $1,758,000 after purchasing an additional 4,934 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of electroCore during the 4th quarter worth approximately $108,000. Northern Trust Corp raised its position in shares of electroCore by 7.7% during the 4th quarter. Northern Trust Corp now owns 66,397 shares of the company’s stock worth $415,000 after purchasing an additional 4,724 shares during the last quarter. Geode Capital Management LLC raised its position in shares of electroCore by 38.1% during the 4th quarter. Geode Capital Management LLC now owns 45,632 shares of the company’s stock worth $285,000 after purchasing an additional 12,578 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new position in shares of electroCore during the 4th quarter worth approximately $85,000. Institutional investors own 15.36% of the company’s stock.

electroCore Company Profile

electroCore, Inc, a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. The company is developing gammaCore, a prescription-only non-invasive VNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults.

Further Reading: Management Fee

Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.